Strategy to Prevent Drug-Related Hypersensitivity in Folate-Targeted Hapten Immunotherapy of Cancer
Open Access
- 1 September 2009
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 11 (3) , 628-638
Abstract
Cancer vaccine/immunotherapy rarely involves systemic administration of an immunogenic compound to an actively immunized host. We have developed such a strategy that utilizes folate to deliver antigenic haptens [e.g., fluorescein (FITC) and dinitrophenyl] to folate receptor-positive tumors in a hapten-pre-vaccinated host. Here, we investigated the safety of this novel approach and developed strategies to prevent drug-related hypersensitivity. Using FITC as the model hapten, we identified a potential source of allergic species in folate–FITC preparations by LC-MS/MS. In mice and guinea pigs, we tested the significance of this impurity by passive cutaneous anaphylaxis and active systemic anaphylaxis assays. We studied the effect of immunogen (e.g., KLH–FITC) dose and derived a desensitization regimen that was further evaluated in a murine tumor model. Administration of folate–FITC with low multi-haptenated contaminants (e.g. bis-FITC) resulted in hypersensitivity in under-immunized animals. However, this drug-related hypersensitivity may be independently prevented by (1) increasing the immunogen dose and/or (2) desensitizing animals with folate–FITC during vaccination. In addition, such manipulation in vivo did not appear to negatively alter the effectiveness of immunotherapy. This study provided confidence on the safety of folate–hapten-targeted cancer immunotherapy in an actively immunized host.Keywords
This publication has 39 references indexed in Scilit:
- A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophagesBlood, 2009
- Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor–Positive Solid TumorsJournal of Nuclear Medicine, 2008
- Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA–MORAb-003Nuclear Medicine and Biology, 2008
- Monoclonal Antibodies in Cancer Therapy: 25 Years of ProgressJournal of Clinical Oncology, 2008
- Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate–targeted immunotherapy in hapten-immunized miceMolecular Cancer Therapeutics, 2006
- Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cellsInternational Journal of Cancer, 2005
- Carboplatin desensitizationAnnals of Allergy, Asthma & Immunology, 2004
- DNA vaccination against the ovarian carcinoma-associated antigen folate receptor α (FRα) induces cytotoxic T lymphocyte and antibody responses in miceCancer Gene Therapy, 1999
- Targeting tumor cells with bispecific antibodies and T cellsJournal of Controlled Release, 1998
- Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal AntibodyJNCI: Journal of the National Cancer Institute, 1995